title: [Cryotherapy percutaneous for renal tumors: Our center's beginning experience].
abstract: OBJECTIVE
  To evaluate oncologic and functional outcomes after percutaneous cryoablation (PCA) for renal masses based on our single center experience.
  
  
  METHODS
  We retrospectively identified 26 patients who underwent PCA for 28 tumors between November 2006 and June 2011. Patient's demographics and baseline clinical characteristics, tumor features, perioperative information, and postoperative outcomes we rerecorded. A biopsy was performed systematically before each procedure. Control imaging was obtained at 1, 3, 6 and 12 months, and yearly thereafter. Oncological outcomes were determined by radiographic evidence of tumor recurrence, which was defined by contrast enhancement at the cryoablation site on control imaging at M3.
  
  
  RESULTS
  Patients had mean age of 70.1 years, mean Charlson comorbidity index (CCI) and body mass index) were 6 and 29 kg/m(2) respectively. There were 11 kidney transplants, including 4 solitary. Mean tumor size was 29.5mm and was represented mainly by clear cell renal cell carcinomas (16/28), endophytic (17/28) and midkidney (14/28) (±9.8). Twenty-five cryoablations were performed percutaneously by two lumbotomy. Mean clearance preoperative MDRD was 66,1 mL/min. Mean length of stay was 3.3 days (±2.2). Intraoperative complications consisted of 2 pneumothorax and 6 minor complications postoperative (Clavien≤2). There were no major complications. Mean follow-up was 27.5 months (±15.7), MDRD clearance distance was 61.9 mL/min. Overall survival and disease-specific survival was 100%, while the recurrence-free survival was 78.6% (5 recurrences and 1 failure treatment).
  
  
  CONCLUSIONS
  The percutaneous cryoablation provides a safe and oncologically to extirpative surgery for renal masses in patients with significant medical comorbidities.
  
  
  METHODS
  5.
authors.affiliation: Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France. Electronic address: lallouefanny@yahoo.fr.
authors.forename: F
authors.initials: F
authors.lastname: Lalloué
authors.affiliation: Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: A
authors.initials: A
authors.lastname: Ruffion
authors.affiliation: Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: P-J
authors.initials: PJ
authors.lastname: Valette
authors.affiliation: Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France.
authors.forename: S
authors.initials: S
authors.lastname: Crouzet
authors.affiliation: Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France.
authors.forename: X
authors.initials: X
authors.lastname: Martin
authors.affiliation: Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France.
authors.forename: O
authors.initials: O
authors.lastname: Rouvière
authors.affiliation: Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France.
authors.forename: P
authors.initials: P
authors.lastname: Paparel
mesh_terms: D000368:Aged; D015992:Body Mass Index; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003452:Cryosurgery / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010535:Laparoscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome
keywords: Ablative treatment; Cancer du rein; Chirurgie conservatrice du rein; Cryotherapy; Cryothérapie; Nephron-sparing surgery; Renal cancer; Traitement ablatif